{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:31:57Z","timestamp":1792481517588,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jaad.2023.07.1024","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T17:34:32Z","timestamp":1691343272000},"page":"1149-1158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5\u00a0years of follow-up"],"prefix":"10.1016","volume":"89","author":[{"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Z.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tofial","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Stakias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Espaillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeeta","family":"Sinvhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9583","key":"10.1016\/j.jaad.2023.07.1024_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2023.07.1024_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.07.1024_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/09546634.2013.826341","article-title":"Biologic fatigue in psoriasis","volume":"25","author":"Levin","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jaad.2023.07.1024_bib4","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2023.07.1024_bib5","series-title":"Prescribing information","year":"2022"},{"issue":"10148","key":"10.1016\/j.jaad.2023.07.1024_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaad.2023.07.1024_bib7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.07.1024_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2023.07.1024_bib9","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.17109","article-title":"Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-na\u00efve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial","volume":"35","author":"Tha\u00e7i","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10198","key":"10.1016\/j.jaad.2023.07.1024_bib10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2023.07.1024_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.07.1024_bib12","doi-asserted-by":"crossref","first-page":"AB88","DOI":"10.1016\/j.jaad.2021.06.375","article-title":"Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to severe plaque psoriasis: results from the 28 week randomized, double-blind period of an ongoing phase 3 study in Brazil","volume":"85","author":"Cestari","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.07.1024_bib13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.07.1024_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40262-019-00842-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of risankizumab in psoriasis patients","volume":"59","author":"Pang","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jaad.2023.07.1024_bib15","first-page":"571","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata","volume":"19","author":"Papp","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2023.07.1024_bib16","series-title":"Surveillance, epidemiology, and end results program. Cancer stat facts: common cancer sites","year":"2022"},{"issue":"7","key":"10.1016\/j.jaad.2023.07.1024_bib17","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.07.1024_bib18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.14068","article-title":"Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States","volume":"173","author":"Kimball","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.07.1024_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2023.07.1024_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2023.07.1024_bib21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","article-title":"Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"30","author":"Menter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2023.07.1024_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Tha\u00e7i","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.07.1024_bib23","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.07.1024_bib24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.07.1024_bib25","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jaad.2023.07.1024_bib26","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"issue":"16","key":"10.1016\/j.jaad.2023.07.1024_bib27","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223024167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223024167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:29:25Z","timestamp":1759274965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223024167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0190962223024167"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1024","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5\u00a0years of follow-up","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}